Literature DB >> 15791570

C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.

Lei Huo1, Jun Sugimura, Maria S Tretiakova, Kurt T Patton, Rohit Gupta, Boris Popov, William B Laskin, Anjana Yeldandi, Bin Tean Teh, Ximing J Yang.   

Abstract

C- kit encodes the membrane-bound tyrosine kinase KIT, whose expression has been identified in several types of human neoplasms. Recently, KIT has been reported to be a marker for chromophobe renal cell carcinoma (RCC) and renal angiomyolipoma. However, expression of this molecule has not been adequately studied in other renal tumors, particularly oncocytoma, which may morphologically resemble chromophobe RCC. In this study, we analyzed c- kit messenger RNA (mRNA) levels in 17 chromophobe RCCs and 20 renal oncocytomas obtained from complementary DNA (cDNA) microarrays. Furthermore, comprehensive immunohistochemical analysis of KIT protein using a monoclonal antibody was performed in 226 renal tumors including chromophobe RCC (n=40), oncocytoma (n=41), clear-cell RCC (n=40), renal angiomyolipoma (n=29), and papillary RCC (n=21) on tissue microarrays (TMAs) and was compared with immunostaining results from 25 chromophobe RCCs and 30 oncocytomas using standard sections. The staining intensity was semiquantitatively graded on a 3-tier scoring system. All chromophobe RCCs and oncocytomas showed significant overexpression of c- kit mRNA. The average increase of mRNA compared with normal kidney tissue was 7.4-fold for chromophobe RCCs and 7.4-fold for oncocytomas. Immunohistochemical expression of KIT was found in most chromophobe RCCs (95% in TMAs and 96% in conventional sections) and oncocytomas (88% in TMAs and 100% in conventional sections) but was infrequently observed in renal angiomyolipomas (17%), papillary RCCs (5%), and clear-cell RCCs (3%). Furthermore, the average KIT immunoreactivity in TMAs was stronger in chromophobe RCC (1.93) and oncocytoma (2.07) than in other subtypes of renal tumors tested, including angiomyolipomas (0.17), papillary RCCs (0.05), and clear-cell RCCs (0.03). In conclusion, we found a significant elevation of c- kit mRNA by cDNA expression microarrays and overexpression of KIT protein by immunohistochemistry not only in chromophobe RCCs but also in oncocytomas. In contrast, immunohistochemical expression of KIT was not detected in most other types of renal cell tumors evaluated. The differential expression of c- kit in these renal tumors may have diagnostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15791570     DOI: 10.1016/j.humpath.2005.01.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.

Authors:  Nizar M Tannir; Elizabeth Plimack; Chaan Ng; Pheroze Tamboli; Nebiyou B Bekele; Lianchun Xiao; Lisa Smith; Zita Lim; Lance Pagliaro; John Araujo; Ana Aparicio; Surena Matin; Christopher G Wood; Eric Jonasch
Journal:  Eur Urol       Date:  2012-06-27       Impact factor: 20.096

2.  Metastatic renal oncocytoma.

Authors:  J D Oxley; J Sullivan; A Mitchelmore; D A Gillatt
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

3.  Accurate molecular classification of renal tumors using microRNA expression.

Authors:  Eddie Fridman; Zohar Dotan; Iris Barshack; Miriam Ben David; Avital Dov; Sarit Tabak; Orit Zion; Sima Benjamin; Hila Benjamin; Hagit Kuker; Camila Avivi; Kinneret Rosenblatt; Sylvie Polak-Charcon; Jacob Ramon; Nitzan Rosenfeld; Yael Spector
Journal:  J Mol Diagn       Date:  2010-07-01       Impact factor: 5.568

4.  Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.

Authors:  Naoto Kuroda; Chiaki Kawada; Kenji Tamura; Makoto Hiroi; Ondrej Hes; Michal Michal; Yukari Wada; Kaori Inoue; Masahiko Ohara; Keiko Mizuno; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-03-23       Impact factor: 2.309

5.  Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.

Authors:  B Walter; A Hartmann; F Hofstädter; K Junker; H Moch; S Bertz; S Denzinger; W Otto; M Gajda; C G Stoehr
Journal:  Virchows Arch       Date:  2012-02-17       Impact factor: 4.064

6.  Similar developmental patterns in immunolocalisation of stem cell factor and KIT in bovine meso- and metanephros.

Authors:  Nikoloz Tsikolia; Michiharu Sakurai; Katharina Spanel-Borowski; Albert M Ricken
Journal:  Histochem Cell Biol       Date:  2010-02-18       Impact factor: 4.304

7.  High endogenous avidin binding activity: an inexpensive and readily available marker for the differential diagnosis of kidney neoplasms.

Authors:  Kazunori Kanehira; Johnny Hu; Thomas Pier; Linda Sebree; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  [Small incidental renal tumors. Evaluation and biological parameters].

Authors:  M Remzi; M Memarsadeghi
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

Review 9.  Tubulocystic oncocytoma of the kidney: a case study and review of literature with focus on implications for differential diagnosis.

Authors:  Qi Zhang; Jie Ma; Cui-Yun Wu; Da-Hong Zhang; Ming Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  Weighted Gene Coexpression Network Analysis to Construct Competitive Endogenous RNA Network in Chromogenic Renal Cell Carcinoma.

Authors:  Yong-Bo Chen; Liang Gao; Jin-Dong Zhang; Jiang Guo; Ping-Hong You; Liang-You Tang; Ying-Wen Liu
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.